![Reman McDonagh](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Oorsprong van het eerstegraads netwerk van Reman McDonagh
Entiteit | Type entiteit | Industrie | |
---|---|---|---|
9
| Private Company | Medical Specialties | 9 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Reman McDonagh via zijn persoonlijke netwerk
Onderneming | Sector | Gelieerde personen | Hoofdpost |
---|---|---|---|
Gish Biomedical, Inc.
![]() Gish Biomedical, Inc. Medical SpecialtiesHealth Technology GISH Biomedical, Inc. designs, manufactures and markets innovative disposable medical devices for cardiovascular surgery, with a focus on the Perfusionist. The GISH product portfolio also includes targeted solutions for vascular access and orthopedics. All GISH products are single use disposable products or have a disposable component. The company's principal products include oxygenators and oxygenator systems, blood reservoirs, cardioplegia delivery systems, custom cardiovascular tubing systems, central venous access catheters and ports, and blood recovery devices for post-operative use in orthopedic surgeries. With a manufacturing facility and offices in Rancho Santa Margarita, California, GISH markets its products worldwide through a combination of direct sales representatives and specialty medical distributors. GISH has been at the forefront of the design and manufacturing of hospital based and operating room medical devices for over 25 years. From simple sets to complex circuits for open heart surgery, precision and quality in manufacturing is what you can rely on from GISH. | Medical Specialties | Chief Executive Officer | |
TIGENIX NV | Medical Specialties | Director/Board Member | |
POXEL | Pharmaceuticals: Major | Director/Board Member | |
Calliditas Therapeutics Suisse SA
![]() Calliditas Therapeutics Suisse SA Pharmaceuticals: GenericHealth Technology Calliditas Therapeutics Suisse SA engages in the development of NOX therapies. Its platform enables the identification of orally available small-molecules that selectively inhibit specific NOX enzymes, which amplify multiple disease processes such as fibrosis, inflammation, pain processing, cancer development, and neurodegeneration. The company was founded Chihiro Yabe, Robert A. Clark, David Lambeth, and Karl-Heinz Krause in 2006 and is headquartered in Geneva, Switzerland. | Pharmaceuticals: Generic | Director/Board Member | |
Sparflex SA
![]() Sparflex SA Industrial MachineryProducer Manufacturing Sparflex SA provides packaging supplies. It offers wire hoods, capsules, and foils. The firm also offers consulting, branding, and design services. The company was founded by Jocelyne Soutiran and Michel Soutiran in 1984 and is headquartered in Epernay, France. | Industrial Machinery | Director/Board Member | |
Goldman Sachs & Co. LLC
![]() Goldman Sachs & Co. LLC Investment Banks/BrokersFinance Goldman Sachs & Co. LLC (GS&Co.) is a securities brokerage firm headquartered in New York City. Founded in 1927, the firm is a subsidiary of The Goldman Sachs Group, Inc. (NYSE: GS). GS&Co. provides services to help hedge funds manage risk, monitor portfolios, maintain liquidity and build their businesses. They offer clients access to global equity and derivatives markets, as well as foreign exchange, commodities, European Lefts, rates and credit across the Americas, Europe and Asia. The firm proactively monitors capital markets, searching for pockets of liquidity and news that may require changes to those strategies. Integration with the Goldman Sachs network gives clients access to the firm's sectored block trades and their insights into price discovery. Their electronic trading program provides clients with tools to manage their trades from pre-trade analytics to post-trade analysis. | Investment Banks/Brokers | Corporate Officer/Principal | |
Auriga Partners SA
![]() Auriga Partners SA Investment ManagersFinance Auriga Partners SA (Auriga) is an independent, management-owned venture capital firm which was founded by Patrick Bamas, Jacques Chatain and Bernard Daugeras in 1998. Headquartered in Paris, the firm's core activity is enterprise creation. In addition to providing a network of contacts capable of accelerating internationalization, and furthering strategic partnerships and business deals, Auriga manages several seed and early-stage funds specializing in information technology and life sciences. | Investment Managers | Director/Board Member | |
VOYAGEURS DU MONDE | Other Consumer Services | Director/Board Member | |
NOXXON Pharma AG
![]() NOXXON Pharma AG BiotechnologyHealth Technology NOXXON Pharma AG operates a clinical stage biotechnology company. Its core focus is on cancer treatment. The firm offers effectiveness of cancer treatments including immuno-oncology approaches such as immune checkpoint inhibition and current standards of care such as chemotherapy and radiotherapy. The company was founded in 1997 by Sven Klussmann, Jens-Peter Fürste and Thomas Klein and is headquartered in Berlin, Germany. | Biotechnology | Director/Board Member | |
Mutabilis SA
![]() Mutabilis SA Pharmaceuticals: MajorHealth Technology Mutabilis SA specializes in the discovery and development of anti-infective drugs. It focuses on novel therapeutic approaches for controlling severe and nosocomial infections. The firm offers antibacterial, vaccines, anti-infective agents, gram-positive & negative ant virulence lead series, specific antigens, and screening technologies for antibacterial and virulence targets. The company was founded in 2001 by Xavier Nassif and is headquartered in Romainville, France. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
INNATE PHARMA | Pharmaceuticals: Major | Director/Board Member | |
Sciences Po | College/University | Graduate Degree | |
ESSEC Business School | College/University | Graduate Degree | |
SUPERSONIC IMAGINE | Medical Specialties | Director/Board Member Director/Board Member Director/Board Member | |
Finovelec | Corporate Officer/Principal | ||
École des Hautes Études Commerciales de Paris | College/University | Graduate Degree Masters Business Admin | |
STENTYS | Medical Specialties | Director/Board Member Director/Board Member | |
NASA Johnson Space Center | General Government | Corporate Officer/Principal | |
EOS IMAGING | Medical Specialties | Director/Board Member Director/Board Member Director/Board Member | |
IMPLANET SA | Medical Specialties | Director/Board Member Director/Board Member | |
AM-Pharma BV
![]() AM-Pharma BV BiotechnologyHealth Technology AM-Pharma BV operates as a biopharmaceutical company. It engages in the development of proprietary recombinant human Alkaline Phosphatase. The firm’s products include Acute Kidney Injury, Inflammatory Bowel Diseases and Hypophosphatasia. The company was founded in 2001 and is headquartered in Bunnik, the Netherlands. | Biotechnology | Director/Board Member | |
MedDay Pharmaceuticals SAS
![]() MedDay Pharmaceuticals SAS BiotechnologyHealth Technology MedDay Pharmaceuticals SAS operates as a biotechnology company developing new drugs for nervous system disorders. The firm operates for the treatment of neuro-metabolic diseases. The company was founded by Frédéric Sedel and Guillaume Brion in 2011 and is headquartered in Paris, France. | Biotechnology | Director/Board Member | |
AXONICS, INC. | Medical Specialties | Chairman | |
Axonics Europe SAS | Chief Executive Officer | ||
SoniVie Ltd.
![]() SoniVie Ltd. Medical SpecialtiesHealth Technology SoniVie Ltd. engages in the development of a system for the treatment of pulmonary hypertension. Its products include Therapeutic Intra-Vascular Ultrasound (TIVUS) system, an intravascular, catheter-based technology that can cause denervation of nerves surrounding blood vessels and other structures like the bronchus. The company was founded by Moshe Arkin in 2014 and is headquartered in Rosh Haayin, Israel. | Medical Specialties | Director/Board Member | |
ReViral Ltd.
![]() ReViral Ltd. BiotechnologyHealth Technology ReViral Ltd. specializes in the areas of virology and antiviral therapies. It offers drugs to treat respiratory synctial virus infection. The company was founded by Neil Matthews and Stuart Cockerill in 2011 and is headquartered in Stevenage, the United Kingdom. | Biotechnology | Director/Board Member | |
Axonics, Inc. (New York) | Director/Board Member | ||
Imcheck Therapeutics SAS
![]() Imcheck Therapeutics SAS Pharmaceuticals: MajorHealth Technology Imcheck Therapeutics SAS operates as a biopharmaceutical company which develops immunotherapeutic anti-cancer strategies for research. The company was founded by Olive Daniel in 2015 and is headquartered in Marseille, France. | Pharmaceuticals: Major | Director/Board Member | |
Dynacure SA
![]() Dynacure SA Medical/Nursing ServicesHealth Services Dynacure SA is a clinical-stage company, which engages in developing and commercializing novel therapies to transform the lives of patients with rare diseases who have limited or no treatment options. Its product includes, DYN101, an antisense oligonucleotide, or ASO, designed to be a disease-modifying medicine for treatment of the majority of ntronuclear myopathies patients with multiple mutations in adult and pediatric populations. The company was founded by Belinda Cowling in 2016 and is headquartered in Illikirch-Graffenstaden, France. | Medical/Nursing Services | Director/Board Member | |
Artios Pharma Ltd.
![]() Artios Pharma Ltd. Pharmaceuticals: MajorHealth Technology Artios Pharma Ltd. manufactures pharmaceutical products. The firm develops a DNA Damage Response (DDR) is a cancer therapy. The company was founded by Niall Martin in May 2016 and is headquartered in London, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
Grey Wolf Therapeutics Ltd.
![]() Grey Wolf Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Grey Wolf Therapeutics Ltd. is a biotechnology company, which engages in the drug discovery in immuno-oncology. It targets endoplasmic reticulum aminopeptidases 1 and 2 in the antigen presentation pathway to drive modulation of the neoantigen repertoire on tumour cells. The company was founded by Thomas D. McCarthy and Peter Joyce and is headquartered in Oxford, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
Gamma Développement
![]() Gamma Développement Miscellaneous Commercial ServicesCommercial Services Gamma Developpement engages in the financial industry providing business strategies and financial support solutions. The company was founded by Jean-Marc Duminil on May 3, 2010 and is headquartered in Combaillaux, France. | Miscellaneous Commercial Services | Director/Board Member | |
Winch Italy Holdings 1 SARL | Corporate Officer/Principal | ||
EPG Investment Partners SA | Chairman | ||
Winch Italy Holding 2 SARL | Director/Board Member |
Statistieken
Internationaal
Frankrijk | 28 |
Verenigde Staten | 9 |
Zwitserland | 5 |
Verenigd Koninkrijk | 5 |
Luxemburg | 4 |
Sectoraal
Health Technology | 29 |
Consumer Services | 7 |
Finance | 6 |
Health Services | 3 |
Producer Manufacturing | 2 |
Operationeel
Director/Board Member | 140 |
Corporate Officer/Principal | 16 |
Independent Dir/Board Member | 13 |
Chairman | 11 |
Chief Executive Officer | 8 |
Sterkste connecties
Insiders | |
---|---|
Raj Bhikhu Parekh | 50 |
Raphaël Wisniewski | 45 |
Philippe Peltier | 45 |
Alexia Perouse | 20 |
Julie Drapier | 10 |
John T. Garibotto | 9 |
Eric Beard | 8 |
Sophie Baratte | 5 |
Julian Shapley | 4 |
- Beurs
- Insiders
- Reman McDonagh
- Bedrijfsconnecties